Objective: We aimed to identify prognostic factors of early-stage cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) treated with primary radical surgery, and to evaluate the impact of postoperative adjuvant therapy on outcome. Methods: The clinical-pathological data of all patients (n ¼ 1132) with stages I-II cervical AC/ASC treated with primary radical surgery at the member hospitals of the Taiwanese Gynecologic Oncology Group were retrospectively reviewed. Results: In multivariate analysis, stage II, deep stromal invasion (DSI), lymphovascular space invasion (LVSI), positive pelvic lymph node (PLN), and parametrial involvement (PI) were significant factors for recurrence-free survival (RFS), while only DSI, PI, and positive PLN were independent factors for cancerspecific survival (CSS). Low-and high-risk groups were defined by prognostic scores derived from the four factors (DSI, LVSI, positive PLN, PI) selected by internal validation. Postoperative adjuvant therapy significantly improved outcome for PLN-positive patients (RFS, p ¼ 0.014; CSS, p ¼ 0.016), but not for Surgical Oncology 25 (2016) 229e235 PLN-negative high-risk group because of higher mean prognostic score (p ¼ 0.028) of adjuvantþ than adjuvantÀ patients. Conclusions: PLN metastasis, PI, DSI, and LVSI were independent prognostic factors. Prospective studies of postoperative adjuvant therapy with prognostic score and nodal status stratification for cervical AC/ ASC are necessary.
Introduction
Cervical cancer is the third most common cancer in female, with estimated 528,000 new cases and 266,000 deaths in 2012 [1] . Most cases are squamous cell carcinoma (SCC) histology. Less common types include adenocarcinoma (AC), adenosquamous carcinoma (ASC) (generally considered together), and other rare types [2] . Currently, ACs and ASCs (AC/ASCs) are treated similar to SCC [2, 3] , though there is increasing evidence suggesting that AC/ASCs behave differently from SCCs [2] . Equal cure rates may be obtained with primary radiation therapy or radical hysterectomy with pelvic lymphadenectomy (RH-PLND) for early-stage cervical cancer [4] . For avoiding the chronic radiation injury, removing the primary tumor, and accurate surgical staging, primary radical surgery for early-stage cervical cancer is preferred, particular in AC [5] . Following RH-PLND, adjuvant therapy is indicated for patients with adverse pathological factors. Several pathological findings such as pelvic lymph node (LN) metastasis, parametrial involvement (PI), and deep stromal invasion (DSI) have been identified as risk factors for recurrence [6, 7] .
For high-risk patients, the hazard ratios (HRs) for progressionfree and overall survival (PFS and OS) of postoperative adjuvant radiotherapy versus chemoradiotherapy were 2.01 (p ¼ 0.003) and 1.96 (p ¼ 0.007), respectively [8] , while adjuvant therapy may reduce recurrence (HR 0.54 95% confidence interval [CI] 0.35e0.81) but may not significantly improve survival (HR 0.70 95%CI 0.45e1.05) in the LN-negative patients with other poor prognostic factors [9] .
Compared to the marked decrease in the incidence of cervical SCC, the incidence of cervical AC/ASC is increasing [10] . Cervical AC/ ASC and SCC could be different in prognostic factors and treatment modality [11, 12] , but most of our knowledge on the studies of prognostic factors and adjuvant therapy for early-stage cervical cancer after primary surgical treatment comes from the patients with SCC [11, 12] .
We aimed to conduct a multicenter retrospective study to identify the prognostic factors of early-stage cervical AC/ASC treated with RH-PLND, and to evaluate the impact of postoperative adjuvant therapy on survival.
Materials and methods

Study population
All women with a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stages I-II cervical AC/ASC who received RH-PLND as a primary treatment at the member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) from January 1991 through December 2011 were included in this study. The study protocol was approved by the institutional review board of each hospital. Medical records were retrospectively reviewed to obtain patient's demographics, surgical-pathologic data, and clinical outcome. All patients were clinically staged using the FIGO 2009 staging system for cervical cancer [13] . Exclusion criteria included histological subtypes other than AC or ASC, greater than FIGO stages I-II, without primary surgical treatment, patients with endometrioid adenocarcinoma from the uterine corpus.
Surgical-pathologic characteristics and adjuvant therapy
The pathologic slides were presented at the multidisciplinary gynecologic oncology tumor board in each hospital. Tumors categorized as ASC showed both invasive AC and SCC elements. Adjuvant therapy was given at discretion of the responsible physician, most of the plans were discussed in a multidisciplinary conference. In general, it was prescribed for the following indications: positive pelvic LN, PI, positive and/or close parametrial or vaginal margins, and DSI (>50%) or large tumor size (>4 cm) with LVSI.
Clinical follow-up consisted of physical examinations, vaginal cytology, tumor markers, and imaging studies. The patients' detailed medical records, which included clinical and pathological characteristics, treatment and outcome information, were retrospectively evaluated until the end of the follow-up period (December 31, 2014).
Statistical analysis
Descriptive statistics were used to present patient characteristics. For time-to-event data, recurrence-free survival (RFS) was calculated as the period from primary surgical treatment to the date of confirmed recurrence or disease progression, or to the last noted date of disease-free status on the medical records. Cancerspecific survival (CSS) was calculated as the time of the initial diagnosis of cervical AC/ASC until the date of disease-related death or last follow-up. Disease-related death was defined as death caused by the malignancy or malignancy-associated complications. Cases lost to follow-up and those alive at the end of the follow-up period were considered censored observations. Survival curves were generated using the Kaplan-Meier method and differences between survival curves were compared using the log-rank test. The univariate analysis was based on Cox regression, and the stepwise multivariate Cox model using forward Wald method was used to determine independent prognostic factors for survival. Outcome predicting models were constructed using the significant covariates for either CSS or RFS. For prognostic score and risk group classification, Mann-Whitney test was used to compare scores between groups, and Goodness of fit of classification model evaluated by chi-square test. Bootstrap resampling [14] was performed randomly to construct new data sets (events per variable >10, n ¼ 1132) followed by Cox regression analysis, which was repeated 1000 times, and the counts of selection as significant were recorded for each variable. Data were analyzed using SPSS software Version 20 (IBM SPSS Statistics 20; SPSS, Chicago, IL), and a p-value <0.05 was defined as statistical significance.
Results
Patient's characteristics
Between January 1, 1991 and December 31, 2011, a total of 1264 patients who received primary surgical treatment for stages I-II cervical AC/ASC were retrieved from the tumor registries of the 17 TGOG member hospitals. Of these 1264 patients, 132 who didn't receive RH-PLND as a primary treatment were excluded from this study. The remaining 1132 patients primarily treated with RH-PLND were eligible for analysis.
The patient's characteristics are shown in Table 1 . The median age of these 1132 patients was 46 years (range: 20e87 years). The median follow-up of censored patients was 76.4 months (range: 0.5e272.4 months). Most (71.6%) of them were grade 1 or grade 2 differentiation and presented as FIGO stage I (86.9%). The mean number of retrieved pelvic LN was 25.4 ± 12.8. Seven hundred and twelve patients (62.9%) did not receive adjuvant treatment after surgery, 141 (12.5%) received radiotherapy alone, 85 (7.5%) chemotherapy alone, and 194 (17.1%) chemoradiotherapy. Positive pelvic LN was found in 210 (18.6%) and PI in 117 (10.4%). Large tumor size (>4 cm) was observed in 167 (14.7%), DSI (>50%) in 449 (39.7%), LVSI in 312 (27.6%), and vaginal involvement in 87 (7.7%).
Analysis of prognostic factors
Univariate analyses by log rank test with 5-year CSS and RFS rates are shown in Table S1 . Univariate Cox regression for CSS and RFS are shown in Tables 2 and 3 . Histology subtype (ASC), FIGO stage II, primary tumor size > 4 cm, DSI, LVSI, positive pelvic LN, PI, and vaginal involvement showed significant adverse effects on both RFS and CSS. Young age ( 45 years old) had a significant beneficial effect on RFS only.
Multivariate analyses by Cox regression for CSS and RFS are shown in Tables 2 and 3 . Three factors including positive pelvic LN (RFS: p < 0.001; CSS: p < 0.001), PI (RFS: p ¼ 0.017; CSS: p < 0.001), and DSI (RFS: p < 0.001; CSS: p ¼ 0.021) had significant effects on both RFS and CSS. FIGO stage II (p ¼ 0.024) and positive LVSI (p ¼ 0.002) were significant poor prognostic factors only for RFS.
Internal validation by bootstrap analyses
The five prognostic factors for CSS and/or RFS were taken into consideration for the further internal validation. Using bootstrapping by resampling 1000 times, it showed that the significant risk factors were the same as the original models for either CSS or RFS except FIGO stage II (Table S2 ). The four factors DSI, LVSI, FIGO International Federation of Gynecology and Obstetrics. HR hazard ratio, CI confidence interval. positive pelvic LN, and PI validated were selected for risk group classification.
Prognostic score and risk group classification
Outcome predicting models were constructed using the four independent covariates for either CSS or RFS. The score was 0 for depth of cervical stromal invasion <50% and 2 (approximate average of 2.29 and 1.65) for stromal invasion S50%; 0 for LVSInegative and 1.5 (nearest approximate of 1.69) for LVSI-positive; 0 for negative pelvic node and 3.5 (approximate average of 2.77 and 4.43) for positive pelvic node; and 0 for no PI and 2 (approximate average of 2.47 and 1.61) for presence of PI. The probability of cancer-specific death was significantly higher in the high-risk group (score S3.5, HR ¼ 6.0 95% CI 4.4e8.1), when compared with the low-risk group (score 0e2, reference) (p < 0.001). The 5year CSS rates were 94.2% and 65.8% for the low-risk and highrisk groups, respectively ( Table 4 ). The probability of cancer recurrence was significantly higher in the high-risk group (HR ¼ 5.2 95% CI 4.0e6.7), when compared with the low-risk group (p < 0.001). The 5-year RFS rates were 88.6% and 55.1%, for the lowrisk and high-risk groups respectively (Table 4 ).
Stratified analysis of survival based on risk group and adjuvant therapy
The impact of adjuvant therapy on CSS and RFS according to risk-groups was shown in Table 5 . There were no significant differences on CSS or RFS of high- (Fig. S1 ) and low-risk groups (Fig. S2 ) with or without adjuvant therapy. Among high-risk patients with pelvic LN metastasis had a significant effect on RFS (p ¼ 0.014) and CSS (p ¼ 0.016) ( Fig. 1) , while LN-negative high-risk patients receiving adjuvant therapy (adjuvantþ) did not have better RFS (p ¼ 0.176) and CSS (p ¼ 0.180) than those without adjuvant therapy (adjuvante) (Fig. S3 ) for the higher mean risk score ( Table 5 ). The mean prognostic scores of adjuvantþ patients were significantly higher than adjuvantÀ in both low-risk (1.4 versus 0.5, p < 0.001) and high-risk group (5.7 versus 4.4, p < 0.001), and pelvic LN-negative high-risk group (3.9 versus 3.6, p ¼ 0.028), while pelvic LN-positive patients did not differ in mean prognostic score (p ¼ 0.293) ( Table 5 ). Stratified by risk factors, adjuvantþ patients tended to be associated with higher mean prognostic score, poorer RFS and CSS as compared with adjuvante, with the exception of the pelvic LN-positive group (Tables S3e6). Among those with LNpositive, patients receiving chemoradiotherapy had marginally better CSS than those receiving radiotherapy alone (5-year CSS 60.6% versus 48.2%, p ¼ 0.088) (Table S5) , although the mean prognostic score of the former was significantly higher than the latter (6.8 versus 6.2, p ¼ 0.018) (Tables S3 and S4 ).
Discussion
Most knowledge regarding the prognostic factors and effect of adjuvant therapy following primary RH-PLND for early-stage cervical cancer comes from patients with SCC [4e9,15e18]. Most published data regarding the prognostic factors and effect of adjuvant therapy for cervical AC/ASC and other rare subtypes have been based on small studies or single institutional studies [11,18e22] . In this TGOG retrospective study (n ¼ 1132), PLN metastasis, PI, DSI, and LVSI were independent prognostic factors for cervical AC/ASC. Low-and high-risk groups were defined by prognostic scores derived from these four factors, and the 5-year RFS and CSS were 88.6% and 94.2%, 55.1% and 65.8%, respectively (RFS: p < 0.001; CSS; p < 0.001).
Lai et al. (n ¼ 456) found no differences in RFS and CSS between the ASC and AC histology [21] . Baek et al. (n ¼ 337) observed no differences in patterns of recurrence, time to recurrence, RFS, and OS between AC and ASC [22] . A Korean multicenter retrospective study (total n ¼ 1323; AC/ASC, n ¼ 255) reported that AC histology was associated with poor survival outcomes than SCC, and prognosis of ASC histology was closer to that of SCC histology [23] . Conversely, a meta-analysis reported that ASC may have poorer outcomes compared with AC of the cervix [24] . Our study demonstrated that ASC seemed slightly worse than AC in univariate analysis, but they were not significantly different on RFS and CSS in multivariate analyses (Tables 2 and 3) .
Age (>50) at diagnosis and FIGO stage were reported to be independent poor prognostic factors in cervical AC/ASC [21] . Baalbergen et al. reported that young age (<35) was a significant good prognostic factor [25] . In our study, age was not significant for RFS and CSS, but FIGO stage (p ¼ 0.024) had significant effects on RFS (Tables 2 and 3 ), but not selected for risk group classification for failed of internal validation (Table S2 ). Baek et al. reported that LVSI and LN metastasis were significantly associated with OS [22] . Kato et al. concluded that LN metastasis, PI, and LVSI were independent prognostic factors for cervical AC treated with surgery [26] . Park et al. also reported that PI and LN metastasis were significant factors for both RFS and OS in patients with early-stage cervical AC after RH [27] .
Yasuda et al. reported that low-risk group of stage IB ASC had a good prognosis without postoperative adjuvant therapy [28] . In our study, CSS and RFS were excellent in the low-risk group with or without adjuvant therapy ( Table 5 ). We confirmed that adjuvant therapy following RH-PLND for early-stage AC/ASC patients with low prognostic score may not improve survival. Therefore, adjuvant therapy could be omitted in order to decrease morbidity.
Cohn et al. also found that a trend of improved survival was observed with the use of adjuvant therapy, specifically the use of combined chemotherapy and radiotherapy after RH in AC patients with LN metastasis [29] . A phase III randomized trial showed that pelvic radiotherapy after RH-PLND prolonged progression-free survival in women with LN-negative stage IB cervical cancer with at least two high risk features (DSI, LVSI, or tumor diameter > 4 cm), radiotherapy appears to be particularly beneficial for patients with AC/ASC [9] . In our study, impact of adjuvant therapy for LNnegative high-risk group was non-significant because of higher prognostic scores of the adjuvantþ than adjuvantÀ patients ( Table 5 ), reflecting the importance of prospective study with prognostic score stratification. Among high-risk patients with pelvic LN metastasis had a significant effect on RFS (p ¼ 0.014) and CSS (p ¼ 0.016). Besides, Those with LN-positive and receiving chemoradiotherapy had marginally better CSS than those receiving radiotherapy alone (p ¼ 0.088), although the mean prognostic score of the former was significantly higher than the latter (p ¼ 0.018) ( Table 5 and Tables S4eS5). Our study suggests that adjuvant chemoradiotherapy might be the choice for patients with pelvic LN metastasis. A randomized phase III trial has shown improved survival for the treatment of advanced cervical cancer adding weekly concurrent gemcitabine and two cycles of adjuvant gemcitabine and cisplatin to standard singleagent concurrent chemoradiotherapy (CCRT) [30] . Besides, a phase III trial on bevacizumab has significantly improved OS in advanced and recurrent cervical cancer [31] . Pazopanib has significant improvements in PFS in a phase II randomized trial [32] . The 5-year CSS of LN-positive patients receiving chemoradiotherapy in this series was 60.6% (Table S4) , further improvement would lies in novel adjuvant combination chemotherapy incorporating target therapeutic agents during and post-CCRT.
The strength of this study is that it includes the largest series of patients with early-stage cervical AC/ASC and offers significant information regarding prognostic factors and adjuvant therapy after RH-PLND. The major limitation of this study is its retrospective nature. The details of regimens and courses of chemotherapy/ chemoradiotherapy are lacking. To date, prospective researches targeting cervical AC/ASC are limited. Despite the limitations, our study suggests that adjuvant therapy has positive impact on survival in stage I-II AC/ASC patients with LN metastasis after primary RH-PLND. Impact of adjuvant therapy for LN-negative high-risk group was non-significant because of higher prognostic scores of the adjuvantþ than adjuvantÀ patients, reflecting the importance of prognostic score stratification in future prospective studies. 
